NASDAQ:SBFM Sunshine Biopharma (SBFM) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free SBFM Stock Alerts $0.84 +0.00 (+0.30%) (As of 05:23 PM ET) Add Compare Share Share Today's Range$0.81▼$0.9250-Day Range$0.81▼$10.8552-Week Range$0.75▼$140.00Volume4.94 million shsAverage Volume1.48 million shsMarket Capitalization$831,600.00P/E RatioN/ADividend YieldN/APrice Target$260.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Sunshine Biopharma alerts: Email Address Sunshine Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside29,781.6% Upside$260.00 Price TargetShort InterestHealthy7.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$10,000 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.47 out of 5 stars 3.5 Analyst's Opinion Consensus RatingSunshine Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSunshine Biopharma has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.32% of the float of Sunshine Biopharma has been sold short.Short Interest Ratio / Days to CoverSunshine Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sunshine Biopharma has recently decreased by 90.12%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSunshine Biopharma does not currently pay a dividend.Dividend GrowthSunshine Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SBFM. Previous Next 3.3 News and Social Media Coverage News SentimentSunshine Biopharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.Search Interest39 people have searched for SBFM on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat Follows11 people have added Sunshine Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sunshine Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders14.70% of the stock of Sunshine Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Sunshine Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sunshine Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSunshine Biopharma has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsFW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. About Sunshine Biopharma Stock (NASDAQ:SBFM)Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in New York, New York.Read More SBFM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SBFM Stock News HeadlinesApril 22, 2024 | msn.comSBFM, BPTH and INDO among pre-market losersApril 19, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.56%May 3, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.April 19, 2024 | finanznachrichten.deSunshine Biopharma, Inc.: Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg, a Biosimilar of NeulastaApril 12, 2024 | finanznachrichten.deSunshine Biopharma, Inc.: Sunshine Biopharma Announces Reverse Stock SplitApril 8, 2024 | investorplace.comSBFM Stock Earnings: Sunshine Biopharma Misses EPS, Beats Revenue for Q4 2023April 4, 2024 | seekingalpha.comSBFM Sunshine Biopharma, Inc.March 6, 2024 | cnn.comSunshine Biopharma IncorporatedMay 3, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.March 4, 2024 | investorplace.comWhy Is Sunshine Biopharma (SBFM) Stock Down 17% Today?February 15, 2024 | finance.yahoo.comSunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public OfferingJanuary 23, 2024 | finance.yahoo.comAnalysts Are Optimistic We'll See A Profit From Sunshine Biopharma, Inc. (NASDAQ:SBFM)November 28, 2023 | benzinga.comSunshine Biopharma Stock (NASDAQ:SBFM) Dividends: History, Yield and DatesSeptember 22, 2023 | finanznachrichten.deSunshine Biopharma, Inc.: Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid ComplianceSeptember 22, 2023 | finance.yahoo.comSunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid ComplianceSeptember 14, 2023 | investopedia.comWhat Are Sunshine Laws? Definition, Purpose, ExamplesSeptember 12, 2023 | finance.yahoo.comIt's Down 26% But Sunshine Biopharma, Inc. (NASDAQ:SBFM) Could Be Riskier Than It LooksAugust 16, 2023 | finance.yahoo.comWhen Will Sunshine Biopharma, Inc. (NASDAQ:SBFM) Breakeven?August 11, 2023 | finanznachrichten.deSunshine Biopharma Inc.: Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%August 11, 2023 | finance.yahoo.comSunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%May 16, 2023 | finanznachrichten.deAegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc.May 16, 2023 | finance.yahoo.comSunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-MarketMay 16, 2023 | finance.yahoo.comAegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)May 12, 2023 | marketwatch.comSunshine Biopharma Shares Slide 22% Premarket on Private Placement >SBFMMay 12, 2023 | msn.comSunshine Biopharma to sell 5.95M units at $0.84 in private placementMay 12, 2023 | investorplace.comSBFM Stock Alert: Why Sunshine Biopharma Is Down 28% TodayMay 12, 2023 | finance.yahoo.comSunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-MarketSee More Headlines Receive SBFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/03/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SBFM CUSIPN/A CIK1402328 Webwww.sunshinebiopharma.com Phone(514) 426-6161FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Target$260.00 High Stock Price Target$260.00 Low Stock Price Target$260.00 Potential Upside/Downside+30,852.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($19.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,510,000.00 Net Margins-18.70% Pretax Margin-17.06% Return on Equity-21.03% Return on Assets-16.32% Debt Debt-to-Equity RatioN/A Current Ratio4.48 Quick Ratio3.45 Sales & Book Value Annual Sales$24.09 million Price / Sales0.03 Cash FlowN/A Price / Cash FlowN/A Book Value$82.58 per share Price / Book0.01Miscellaneous Outstanding Shares990,000Free Float849,000Market Cap$831,600.00 OptionableNot Optionable Beta1.64 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Camille Sebaaly (Age 65)CFO & Secretary Comp: $695kDr. Abderrazzak Merzouki (Age 60)Chief Science Officer & Director Comp: $340kDr. Steve N. Slilaty Ph.D. (Age 72)CEO, President & Chairman Comp: $430kMr. Marc Beaudoin (Age 57)Chief Operating Officer Mr. Malek Chamoun (Age 39)Chief Development Officer Mr. Robert G. Ferreira (Age 62)President of Sunshine Bio Investments Inc More ExecutivesKey CompetitorsEvelo BiosciencesNASDAQ:EVLOEvofem BiosciencesNASDAQ:EVFMSciSparcNASDAQ:SPRCBellerophon TherapeuticsNASDAQ:BLPHAditxtNASDAQ:ADTXView All CompetitorsInsiders & InstitutionsSteve N SlilatyBought 1,000 shares on 3/4/2024Total: $10,000.00 ($10.00/share)Armistice Capital LLCBought 1,156,000 shares on 2/13/2024Ownership: 8.294%View All Insider TransactionsView All Institutional Transactions SBFM Stock Analysis - Frequently Asked Questions Should I buy or sell Sunshine Biopharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunshine Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SBFM shares. View SBFM analyst ratings or view top-rated stocks. What is Sunshine Biopharma's stock price target for 2024? 1 analysts have issued 1-year price objectives for Sunshine Biopharma's stock. Their SBFM share price targets range from $260.00 to $260.00. On average, they expect the company's share price to reach $260.00 in the next year. This suggests a possible upside of 29,781.6% from the stock's current price. View analysts price targets for SBFM or view top-rated stocks among Wall Street analysts. How have SBFM shares performed in 2024? Sunshine Biopharma's stock was trading at $27.15 at the start of the year. Since then, SBFM stock has decreased by 96.8% and is now trading at $0.8701. View the best growth stocks for 2024 here. Are investors shorting Sunshine Biopharma? Sunshine Biopharma saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 69,800 shares, a decline of 90.1% from the March 31st total of 706,700 shares. Based on an average daily trading volume, of 881,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 7.3% of the shares of the stock are short sold. View Sunshine Biopharma's Short Interest. When is Sunshine Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SBFM earnings forecast. How were Sunshine Biopharma's earnings last quarter? Sunshine Biopharma, Inc. (NASDAQ:SBFM) posted its earnings results on Thursday, March, 28th. The company reported ($5.00) earnings per share for the quarter. The firm had revenue of $7.68 million for the quarter. Sunshine Biopharma had a negative net margin of 18.70% and a negative trailing twelve-month return on equity of 21.03%. When did Sunshine Biopharma's stock split? Sunshine Biopharma's stock reverse split before market open on Wednesday, April 17th 2024. The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Sunshine Biopharma? Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SBFM) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryCould Your Accounts Be Frozen?Allegiance GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Gold Grab of the CenturyColonial MetalsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsREAD THIS – If You Missed Out On The AI BoomBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
